

## King's Research Portal

DOI:

[10.1038/ng.1017](https://doi.org/10.1038/ng.1017)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Paternoster, L., Standl, M., Chen, C-M., Ramasamy, A., Bonnelykke, K., Duijts, L., Ferreira, M. A., Alves, A. C., Thyssen, J. P., Albrecht, E., Baurecht, H., Feenstra, B., Sleiman, P. M. A., Hysi, P., Warrington, N. M., Curjuric, I., Myhre, R., Curtin, J. A., Groen-Blokhuys, M. M., ... Weidinger, S. (2012). Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. *Nature Genetics*, 44(2), 187-192. <https://doi.org/10.1038/ng.1017>

### Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### Take down policy

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

Published in final edited form as:

Nat Genet. ; 44(2): 187–192. doi:10.1038/ng.1017.

## META-ANALYSIS OF GENOME-WIDE ASSOCIATION STUDIES IDENTIFIES THREE NEW RISK LOCI FOR ATOPIC DERMATITIS

Lavinia Paternoster<sup>1,75</sup>, Marie Standl<sup>2,75</sup>, Chih-Mei Chen<sup>3</sup>, Adaikalavan Ramasamy<sup>4,5,6</sup>, Klaus Bønnelykke<sup>7</sup>, Liesbeth Duijts<sup>8,9,10</sup>, Manuel A Ferreira<sup>11</sup>, Alexessander Couto Alves<sup>5</sup>, Jacob P Thyssen<sup>12</sup>, Eva Albrecht<sup>13</sup>, Hansjörg Baurecht<sup>14,15,16</sup>, Bjarke Feenstra<sup>17</sup>, Patrick MA Sleiman<sup>18</sup>, Pirro Hysi<sup>19</sup>, Nicole M Warrington<sup>20</sup>, Ivan Curjuric<sup>21,22</sup>, Ronny Myhre<sup>23</sup>, John A Curtin<sup>24</sup>, Maria M Groen-Blokhuis<sup>25</sup>, Marjan Kerkhof<sup>26</sup>, Annika Sääf<sup>27</sup>, Andre Franke<sup>28</sup>, David Ellinghaus<sup>28</sup>, Regina Fölster-Holst<sup>29</sup>, Emmanouil Dermizakis<sup>30,31</sup>, Stephen B Montgomery<sup>30,31</sup>, Holger Prokisch<sup>32,33</sup>, Katharina Heim<sup>33</sup>, Anna-Liisa Hartikainen<sup>34</sup>, Anneli Pouta<sup>34,35</sup>, Juha Pekkanen<sup>36</sup>, Alexandra IF Blakemore<sup>37</sup>, Jessica L Buxton<sup>37</sup>, Marika Kaakinen<sup>38</sup>, David L Duffy<sup>11</sup>, Pamela A Madden<sup>39</sup>, Andrew C Heath<sup>39</sup>, Grant W Montgomery<sup>11</sup>, Philip J Thompson<sup>40</sup>, Melanie C Matheson<sup>41</sup>, Peter Le Souëf<sup>42</sup>, AAGC collaborators<sup>43</sup>, Beate St Pourcain<sup>44</sup>, George Davey Smith<sup>1</sup>, John Henderson<sup>44</sup>, John P Kemp<sup>1</sup>, Nicholas J Timpson<sup>1</sup>, Panos Deloukas<sup>31</sup>, Susan M Ring<sup>44</sup>, H-Erich Wichmann<sup>2,45,46</sup>, Martina Müller-Nurasyid<sup>13,47,48</sup>, Natalija Novak<sup>49</sup>, Norman Klopp<sup>50</sup>, Elke Rodríguez<sup>14,15</sup>, Wendy McArdle<sup>51</sup>, Allan Linneberg<sup>52</sup>, Torkil Menné<sup>12</sup>, Ellen A Nohr<sup>53</sup>, Albert Hofman<sup>8,9</sup>, André G Uitterlinden<sup>8,9,54</sup>, Cornélia M van Duijn<sup>9</sup>, Fernando Rivadeneira<sup>8,9,54</sup>, Johan C de Jongste<sup>10</sup>, Ralf JP van der Valk<sup>8,9,10</sup>, Matthias Wjst<sup>55</sup>, Rain Jogi<sup>56</sup>, Frank Geller<sup>17</sup>, Heather A Boyd<sup>17</sup>, Jeffrey C Murray<sup>57</sup>, Cecilia Kim<sup>18</sup>, Frank Mentch<sup>18</sup>, Michael March<sup>18</sup>, Massimo Mangino<sup>19</sup>, Tim D Spector<sup>19</sup>, Veronique Bataille<sup>19</sup>, Craig E Pennell<sup>20</sup>, Patrick G Holt<sup>58</sup>, Peter Sly<sup>59</sup>, Carla MT Tiesler<sup>2,60</sup>, Elisabeth Thiering<sup>2</sup>, Thomas Illig<sup>50</sup>, Medea Imboden<sup>21,22</sup>, Wenche Nystad<sup>61</sup>, Angela Simpson<sup>24</sup>, Jouke-Jan Hottenga<sup>25</sup>, Dirkje Postma<sup>62</sup>, Gerard H Koppelman<sup>63</sup>, Henriette A Smit<sup>64</sup>, Cilla Söderhäll<sup>65</sup>, Bo Chawes<sup>7</sup>, Eskil Kreiner-Møller<sup>7</sup>, Hans Bisgaard<sup>7</sup>, Erik Melén<sup>27,66</sup>, Dorret I Boomsma<sup>25</sup>, Adnan Custovic<sup>24</sup>, Bo Jacobsson<sup>23,67</sup>, Nicole M Probst-Hensch<sup>21,22</sup>, Lyle J Palmer<sup>68</sup>, Daniel Glass<sup>19</sup>, Hakon Hakonarson<sup>18,69</sup>, Mads Melbye<sup>17</sup>, Deborah L Jarvis<sup>4</sup>, Vincent WV Jaddoe<sup>8,9,70</sup>, Christian Gieger<sup>13</sup>, The GOYA consortium<sup>71</sup>, David P Strachan<sup>72</sup>, Nicholas G Martin<sup>11</sup>, Marjo-Riitta Jarvelin<sup>5,73,74</sup>, Joachim Heinrich<sup>2,76</sup>, David M Evans<sup>1,76</sup>, and Stephan Weidinger<sup>29,76</sup> for the EARly Genetics and Lifecourse Epidemiology (EAGLE) Consortium

<sup>1</sup>MRC CAITE centre, School of Social & Community Medicine, University of Bristol, Bristol, UK

<sup>2</sup>Institute of Epidemiology I, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany <sup>3</sup>Hannover Medical School, Department for Paediatric Pneumology, Allergy and Neonatology, Hannover, Germany <sup>4</sup>Respiratory Epidemiology and Public Health, Imperial College London, United Kingdom <sup>5</sup>Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, United Kingdom <sup>6</sup>Department of Medical and Molecular Genetics, Kings College London, Guy's Hospital, London, United Kingdom <sup>7</sup>COPSAC, Copenhagen Prospective Studies on Asthma in Childhood; Health Sciences, University of Copenhagen & Copenhagen University Hospital, Gentofte, Denmark <sup>8</sup>The Generation R Study Group, Erasmus Medical Center, Rotterdam, The Netherlands. <sup>9</sup>Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands <sup>10</sup>Department of Pediatrics, Division of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands <sup>11</sup>Queensland Institute of Medical Research, Brisbane, Australia <sup>12</sup>National Allergy Research Centre, Department of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Denmark <sup>13</sup>Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany <sup>14</sup>Department of Dermatology and Allergy, Technische Universität München, Munich, Germany

<sup>15</sup>ZAUM-Center for Allergy and Environment, Helmholtz-Zentrum and Technische Universität, Munich, Germany <sup>16</sup>Graduate School of Information Science in Health, Technische Universität München, Munich, Germany <sup>17</sup>Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark <sup>18</sup>The Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA <sup>19</sup>Department of Twin Research and Genetic Epidemiology, King's College London <sup>20</sup>School of Women's and Infants' Health, The University of Western Australia, Western Australia, Australia <sup>21</sup>Swiss Tropical and Public Health Institute (SwissTPH), Basel, Switzerland <sup>22</sup>University of Basel, Basel, Switzerland <sup>23</sup>Norwegian Institute of Public Health, Department of Genes and Environment, Division of Epidemiology, Oslo, Norway <sup>24</sup>The University of Manchester, Manchester Academic Health Science Centre, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK <sup>25</sup>Department of Biological Psychology, VU University, Amsterdam, The Netherlands. <sup>26</sup>Department of Pediatric Pulmonology and Allergology, University Medical Center Groningen, University of Groningen, GRIAC research institute, Groningen, The Netherlands <sup>27</sup>Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden <sup>28</sup>Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Kiel, Germany <sup>29</sup>Department of Dermatology, Allergology, and Venerology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany <sup>30</sup>Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, 1211 Switzerland <sup>31</sup>Wellcome Trust Sanger Institute, Cambridge, United Kingdom <sup>32</sup>Institute of Human Genetics, Technische Universität München, Munich, Germany <sup>33</sup>Institute of Human Genetics, Helmholtz Zentrum München – German Research Center for Environmental Health, Neuherberg, Germany <sup>34</sup>Department of Obstetrics and Gynaecology, University of Oulu <sup>35</sup>Department of Children, Young People and Families, National Institute for Health and Welfare, Finland <sup>36</sup>Department of Environmental Health, National Institute for Health and Welfare (THL), Kuopio, Finland <sup>37</sup>School of Public Health, Imperial College London <sup>38</sup>Institute of Health Sciences, University of Oulu, Oulu, Finland <sup>39</sup>Biocenter Oulu, University of Oulu, Oulu, Finland <sup>40</sup>Lung Institute of Western Australia (WA) and Centre for Asthma, Allergy and Respiratory Research, University of WA, Perth, Australia <sup>41</sup>Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Melbourne, Australia <sup>42</sup>School of Paediatrics and Child Health, Princess Margaret Hospital for Children, Perth, Australia <sup>43</sup>Australian Asthma Genetics Consortium, a full list of collaborators is included in the Supplementary Note. <sup>44</sup>The School of Social & Community Medicine, University of Bristol, Bristol, UK <sup>45</sup>Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany <sup>46</sup>Klinikum Grosshadern, Munich, Germany <sup>47</sup>Institute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology and Chair of Genetic Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany <sup>48</sup>Department of Medicine I, University Hospital Grosshadern, Ludwig-Maximilians-Universität, Munich, Germany <sup>49</sup>Department of Dermatology and Allergy, University of Bonn Medical Center, Bonn, Germany <sup>50</sup>Unit for Molecular Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany <sup>51</sup>University of Bristol, ALSPAC Laboratory, School of Social & Community Medicine, University of Bristol, Bristol, UK <sup>52</sup>Research Center for Prevention and Health, Glostrup University Hospital, Denmark <sup>53</sup>Institute of Public Health, Aarhus University, Denmark <sup>54</sup>Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands <sup>55</sup>Comprehensive Pneumology Center and Institute of Lung Biology and Disease, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany <sup>56</sup>Lung Clinic, Tartu University, Tartu, Estonia <sup>57</sup>Department of Pediatrics, University of Iowa, Iowa City, USA <sup>58</sup>Telethon Institute for Child Health Research and Centre for Child Health Research, The University of Western Australia, Western Australia, Australia <sup>59</sup>Queensland Children's Medical Research Institute; University of Queensland; WHO Collaborating Centre for Research on Children's Environmental Health, Queensland, Australia

<sup>60</sup>Division of Metabolic Diseases and Nutritional Medicine, Dr von Hauner Children's Hospital, Ludwig-Maximilians University Munich, Munich, Germany <sup>61</sup>Norwegian Institute of Public Health, Division of Epidemiology, Oslo, Norway <sup>62</sup>Department of Pulmonology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands <sup>63</sup>Dpt of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children's Hospital, GRIAC research institute, University Medical Center Groningen, University of Groningen, The Netherlands <sup>64</sup>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands <sup>65</sup>Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden <sup>66</sup>Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden <sup>67</sup>Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Sahlgrenska Academy, Göteborg University, Sweden <sup>68</sup>Ontario Institute for Cancer Research, Toronto; University of Toronto, Toronto, Canada <sup>69</sup>Department of Pediatric, University of Pennsylvania School of Medicine, Philadelphia, PA, USA <sup>70</sup>Department of Pediatrics, Erasmus Medical Center, Rotterdam, The Netherlands <sup>71</sup>The Genetics of Overweight Young Adults consortium, list of members in Supplementary Note <sup>72</sup>Division of Population Health Sciences and Education, St George's, University of London, London, UK <sup>73</sup>Institute of Health Sciences, Biocenter, University of Oulu, Finland <sup>74</sup>National Institute of Health and Welfare, Finland

## Abstract

Atopic dermatitis (AD) is a common chronic skin disease with high heritability. Apart from filaggrin (*FLG*), the genes influencing AD are largely unknown. We conducted a genome-wide association meta-analysis of 5,606 cases and 20,565 controls from 16 population-based cohorts and followed up the ten most strongly associated novel markers in a further 5,419 cases and 19,833 controls from 14 studies. Three SNPs met genome-wide significance in the discovery and replication cohorts combined: rs479844 upstream of *OVOL1* (OR=0.88,  $p=1.1 \times 10^{-13}$ ) and rs2164983 near *ACTL9* (OR=1.16,  $p=7.1 \times 10^{-9}$ ), genes which have been implicated in epidermal proliferation and differentiation, as well as rs2897442 in *KIF3A* within the cytokine cluster on 5q31.1 (OR=1.11,  $p=3.8 \times 10^{-8}$ ). We also replicated the *FLG* locus and two recently identified association signals at 11q13.5 (rs7927894,  $p=0.008$ ) and 20q13.3 (rs6010620,  $p=0.002$ ). Our results underline the importance of both epidermal barrier function and immune dysregulation in AD pathogenesis.

Atopic dermatitis (AD), or eczema, is one of the most common chronic inflammatory skin diseases with prevalence rates of up to 20% in children and 3% in adults. It commonly starts during infancy and frequently precedes or co-occurs with food allergy, asthma and rhinitis<sup>1</sup>. AD shows a broad spectrum of clinical manifestations and is characterized by dry skin, intense pruritus, and a typical age-related distribution of inflammatory lesions with frequent bacterial and viral superinfections<sup>1</sup>. Profound alterations in skin barrier function and immunologic abnormalities are considered key components affecting the development and severity of AD, but the exact cellular and molecular mechanisms remain incompletely understood<sup>1</sup>.

There is substantial evidence in support of a strong genetic component in AD; however, knowledge on the genetic susceptibility to AD is rather limited<sup>2,3</sup>. So far, only null mutations in the epidermal structural protein filaggrin gene (*FLG*) have been established as major risk factors<sup>4,5</sup>.

The only genome-wide association study (GWAS) on AD in European populations so far identified a novel susceptibility locus on 11q13.5, downstream of *C11orf30*. A recent second GWAS in a Chinese Han population identified two novel loci, one of which also

showed evidence for association in a German sample (rs6010620, 20q13.33)<sup>7</sup>. In a collaborative effort to unravel additional risk genes for AD, we conducted a well powered two-staged genome-wide association meta-analysis in The EARly Genetics and Lifecourse Epidemiology (EAGLE) Consortium.

In the discovery analysis of 5,606 AD cases and 20,565 controls from 16 population-based cohorts of European descent (Supplementary Tables 1,2) there was little evidence for population stratification at study level ( $\lambda_{GC} \leq 1.08$ ) or at the meta-analysis level ( $\lambda_{GC} = 1.02$ ), but an excess of association signals beyond those expected by chance (Supplementary Figs.1,2).

SNPs from two regions reached genome-wide significance in the discovery meta-analysis (Fig.1; Supplementary Table 3): rs7000782 (8q21.13, *ZBTB10*, OR=1.14,  $p=1.6 \times 10^{-8}$ ) and rs9050 (1q21.3, *TCHH*, OR=1.33,  $p=1.9 \times 10^{-8}$ ). Given the proximity of rs9050 to the well-established AD susceptibility gene *FLG*<sup>4,5</sup>, we evaluated whether the observed association was due to linkage disequilibrium (LD) with *FLG* mutations. Despite low correlation between rs9050 and the two most prevalent *FLG* mutations (in ALSPAC (The Avon Longitudinal Study of Parents and Children):  $r^2=0.257$  for R501X,  $r^2=0.001$  for 2282del4) and high levels of recombination (peak of 20cM/Mb at ~150.4Mb in HapMap) between the *TCHH* and *FLG* regions, in a meta-analysis across eight studies conditional on the two *FLG* mutations, rs9050 was no longer associated with AD (OR=0.98,  $p=0.88$ ) (Supplementary Fig.3) and was therefore not investigated further. rs9050 might tag a far-reaching haplotype on which the *FLG* null mutations occur, but we cannot exclude that there are additional AD risk variants in this complex region.

The 11q13.5 locus previously reported to be associated in the only other European GWAS on AD to date<sup>6</sup> was confirmed in our meta-analysis (rs7927894  $p=0.008$ , OR=1.07, 95% CI 1.02-1.12) (Supplementary Fig.4). So was the variant rs6010620 reported in a recent Chinese GWAS<sup>7</sup> ( $p=0.002$ , OR=1.09, 95% CI 1.03-1.15).

Of the 15 loci reported to be associated with asthma or total serum IgE levels in a recent GWAS<sup>8</sup>, two showed suggestive evidence for association with AD (*IL13*:rs1295686,  $p=0.0008$  and rs20541,  $p=0.0007$ ; *STAT6*:rs167769  $p=0.0379$ ) (Supplementary Table 4).

After excluding the rs9050 SNP, we attempted to replicate the remaining 10 most strongly associated loci ( $P < 10^{-5}$  in discovery, Table 1; Supplementary Table 3; Fig.2; Supplementary Fig.5) in 5,419 cases and 19,833 controls from 14 studies (Supplementary Tables 1,2). Three of the ten SNPs showed significant association after conservative Bonferroni correction ( $p < 0.05/10 = 0.005$ ) in the replication meta-analysis (and same direction of effect as the discovery meta-analysis): rs479844 near *OVOL1*, rs2164983 near *ACTL9*, and rs2897442 in intron 8 of *KIF3A* (Table 1; Fig. 2). All three SNPs reached genome-wide significance in the combined meta-analysis of discovery and replication sets: rs479844 ( $p=1.1 \times 10^{-13}$ , OR=0.88), rs2164983 ( $p=7.1 \times 10^{-9}$ , OR=1.16) and rs2897442 ( $p=3.8 \times 10^{-8}$ , OR=1.11). In contrast, rs7000782, which had reached genome-wide significance in the discovery analysis, showed no evidence of association in replication ( $p=0.296$ ). There was no evidence of interactions between the three replicated SNPs (Supplementary Table 5).

rs479844 (at 11q13.1) is located <3kb upstream of *OVOL1*. The pattern of LD is complex at this locus, but there is low recombination between rs479844 and this gene in Europeans (Supplementary Fig.2). *OVOL1* belongs to a highly conserved family of genes involved in the regulation of the development and differentiation of epithelial tissues and germ cells<sup>9-11</sup>. It acts as a c-Myc repressor in keratinocytes, is activated by the  $\beta$ -catenin-LEF1 complex during epidermal differentiation, and represents a downstream target of Wg/Wnt and TGF- $\beta$ /BMP7-Smad4 developmental signaling pathways<sup>10,12,13</sup>. Apart from their role in the



organogenesis of skin and skin appendages<sup>14,15</sup>, these pathways are also implicated in the postnatal regulation of epidermal proliferation and differentiation<sup>16-18</sup>. Disruption of *OVOL1* in mice leads to keratinocyte hyperproliferation, hair shaft abnormalities, kidney cysts, and defective spermatogenesis<sup>10,11</sup>. In addition, *OVOL1* regulates loricrin expression thereby preventing premature terminal differentiation<sup>10</sup>. Thus, it might be speculated whether variation at this locus influences epidermal proliferation and/or differentiation, which is known to be disturbed in AD. Analysis of transcript levels of all genes within 500 kb of rs479844 (*OVOL1*) in EBV-transformed lymphoblastoid cell lines (LCLs) from 949 ALSPAC individuals revealed a significant association between rs479844 and a nearby hypothetical protein DKFZp761E198 ( $p=7\times 10^{-5}$ ). Likewise, analysis of SNP-transcript pairs in the MuTHER (Multiple Tissue Human Expression Resource) skin genome-wide expression quantitative trait loci (eQTL) pilot database of 160 samples<sup>19</sup> provided suggestive evidence for an association in the same direction with DKFZp761E198 in one of the twin sets (Supplementary Fig.6). Further investigations are needed to clarify if the causal variant(s) at this locus exerts its effect through this transcript.

rs2164983 (at 19p13.2) is located in an intergenic region 70kb upstream of *ADAMTS10* and 18kb downstream of *ACTL9* (encoding a hypothetical protein). ADAMTS are a group of complex secreted zinc-dependent metalloproteinases, which bind to and cleave extracellular matrix components, and are involved in connective tissue remodelling and extracellular matrix turnover<sup>20,21</sup>. Actin proteins have well-characterized cytoskeletal functions, are important for the maintenance of epithelial morphology and cell migration, and have also been implicated in nuclear activities<sup>22-24</sup>. The low recombination between rs2164983 and *ACTL9* and recombination peak between rs2164983 and *ADAMTS10* in CEU HapMap individuals (Supplementary Fig.2) suggests the functional variant may be located within the *ACTL9* region. There was no evidence for association between this SNP and any expression level of genes within 500kb in the ALSPAC LCL eQTL analysis, nor the MuTHER skin eQTL data (Supplementary Fig.6).

rs2897442 is located in intron 8 of *KIF3A*, which encodes a subunit of kinesin-II complex, required for the assembly of primary cilia, essential for Hedgehog signaling and implicated in  $\beta$ -catenin-dependent Wnt signaling to induce expression of a variety of genes that influence proliferation and apoptosis<sup>25,26</sup>. Of note, *KIF3A* is located in the 5q31 region, which is characterized by a complex LD pattern and contains a cluster of cytokine and immune-related genes, and has been linked to several autoimmune or inflammatory diseases, including psoriasis<sup>27,28</sup>, Crohn's disease<sup>29,30</sup>, and asthma

<sup>8,29,31</sup> (Supplementary Table 4). In particular, distinct functional *IL13* variants have been associated with asthma susceptibility<sup>32</sup>. Although rs2897442 is within the *KIF3A* gene, there is little recombination between this region and *IL4* (interleukin 4). But there does appear to be a recombination peak between this region and *IL13* (Supplementary Fig.7a). However, a secondary signal also appears to be present in the *IL13/RAD50* region, and when conditioning on rs2897442 in our discovery meta-analysis, the signal in the *IL13/RAD50* region remains, providing evidence of two independent signals (Supplementary Fig. 7b). In an attempt to refine the association at this locus further, we analysed Immunochip data from 1,553 German AD cases and 3,640 population controls, 767 and 983 of which were part of the replication stage. The Immunochip is a custom content Illumina iSelect array focusing on autoimmune disorders, and offers an increased resolution at 5q31. In the population tested, the strongest signal was seen for the *IL13* SNP rs848 ( $p=1.93\times 10^{-10}$ ), which is in high LD with the functional *IL13* variant rs20541 ( $r^2=0.979$ ,  $D'=0.995$ ). Further significant signals were observed for a cluster of tightly linked variants in *IL4* (lead SNP rs66913936,  $p=2.58\times 10^{-8}$ ) and *KIF3A* (rs2897442,  $p=8.84\times 10^{-7}$ ) (Supplementary Tables 6,7; Supplementary Fig.8). While rs2897442 showed only weak LD with rs848 ( $r^2=0.160$ ,

$D'=0.483$ ), it was strongly correlated with rs66913936 ( $r^2=0.858$ ,  $D'=0.982$ ). Likewise, pair-wise genotype-conditioned analyses showed that the significant association of rs2897442 with AD was abolished upon conditioning on rs66913936, whereas there was a remaining signal after conditioning on rs848 (Supplementary Tables 6,7). Analysis of LCL expression levels of all genes within 500kb of rs2897442 in ALSPAC revealed a modest association between rs2897442 and *IL13* transcript levels ( $p=2.7\times 10^{-3}$ ). No associations with any transcript levels within 500kb of the proxy variant rs2299009 ( $r^2=1$ ) were seen in the MuTHER skin eQTL data (Supplementary Fig.6). However, this does not exclude a regulatory effect in another tissue or physiological state, involvement of causative variants in LD with these SNPs in long-range control of more distant genes<sup>33</sup>, or different functional effects such as alternative splicing.

It is well known that genes that participate in the same pathway tend to be adjacent in the human genome and coordinately regulated<sup>34</sup>. Thus, our results and previous findings suggest that there are distinct effects at this locus, which might be part of a regulatory block. Further efforts including detailed sequencing and functional exploration are necessary to fully explore this locus.

Variants rs2164983, rs1327914 and rs10983837 showed evidence of heterogeneity in the meta-analysis ( $p<0.01$ ). The overall random effects results for these variants were  $OR=1.14$  (95%CI 1.05 - 1.24),  $p=0.001$ ;  $OR=1.06$  (95%CI 1.00 - 1.13),  $p=0.058$ ; and  $OR=1.11$  (95%CI 0.98 - 1.20)  $p=0.155$ , respectively. Stratified analysis showed that the effects of rs2164983 and rs1327914 were stronger in the childhood AD cohorts ( $OR=1.23$ ,  $p=2.9\times 10^{-9}$ ;  $OR=1.12$ ,  $p=2.5\times 10^{-4}$ ) as compared to those studies that included AD cases of any age ( $OR=1.17$ ,  $p=0.002$ ;  $OR=1.02$ ,  $p=0.584$ ,  $p$ -value for the differences  $p=0.031$  and  $p=0.028$ , respectively) (Supplementary Fig.9). This did not fully explain the heterogeneity for rs2164983 (in the childhood only cohorts the  $p$ -value for heterogeneity was still  $p<0.01$ ). COPSAC (Copenhagen Studies on Asthma in Children) is noticeably in the opposite direction and excluding this study gives a heterogeneity  $p$ -value of 0.069 ( $OR=1.17$ ,  $p=8.1\times 10^{-10}$ ). However, COPSAC is diagnostically and demographically comparable to the other cohorts and so there is no obvious reason why this cohort should give such a different result. Neither stratification by age of diagnosis nor whether a physician's diagnosis was a case criterion explained the heterogeneity observed for rs10983837. Stratified analyses also indicated a stronger effect of rs2897442 in studies with a more stringent definition of AD (reported physician's diagnosis) ( $OR=1.14$ ,  $p=7.0\times 10^{-9}$ ) as compared to studies where AD was defined as self-reported history of AD only ( $OR=1.05$ ,  $p=0.119$ ) (Supplementary Fig.9). These observations underline the importance of careful phenotyping and support the claim of distinct disease entities rather than one illness as is reflected by current rather broad and inclusive concepts of AD. It is anticipated that the results of molecular studies will enable a more precise classification of AD.

In summary, in this large-scale GWAS on 11,025 AD cases and 40,398 controls we have identified and replicated two novel AD risk loci near genes which have annotations that suggest a role in epidermal proliferation and differentiation, supporting the importance of abnormalities in skin barrier function in the pathobiology of AD. In addition, we observed a genome-wide significant association signal from within the cytokine cluster on 5q31.1, this appeared to be due to two distinct signals, one centered on *RAD50/IL13* and the other on *IL4/KIF3A*, both of which showed moderate association with *IL13* expression. We further observed a signal in the epidermal differentiation complex, representing the *FLG* locus, and replicated the 11q13.5 variant identified in the only other (smaller) European GWAS on AD published to date. Our results are consistent with the hypothesis that AD is caused by both epidermal barrier abnormalities and immunological features. Further studies are needed to

identify the causal variants at these loci and to understand the mechanisms through which they confer AD risk.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Footnotes

**Corresponding Author: Lavinia Paternoster**, MRC CaiTE centre, School of Social and Community Medicine, University of Bristol, Oakfield Road, Bristol, BS8 2BN, UK, l.paternoster@bristol.ac.uk,  
**Telephone:** +44 (0)117 3310135

<sup>75</sup>These authors contributed equally to this work.

<sup>76</sup>These authors jointly directed this work.

### Author Contributions

**Study level data analysis** L Paternoster, M Standl, A Ramasamy, K Bønnelykke, L Duijts, MA Ferreira, AC Alves, JP Thyssen, E Albrecht, H Baurecht, B Feenstra, P Hysi, NM Warrington, I Curjuric, R Myhre, JA Curtin, MM Groen-Blokhuis, M Kerkhof, A Sääf, A Franke, D Ellinghaus, SB Montgomery, BS Pourcain, JP Kemp, NJ Timpson, M Müller-Nurasyid, F Geller, M March, M Mangino, TD Spector, V Bataille, CMT Tiesler, E Thiering, M Imboden, A Simpson, JJ Hottenga, HA Smit, B Chawes, E Kreiner-Møller, E Melén, A Custovic, B Jacobsson, NM Probst-Hensch, D Glass, DL Jarvis, D Strachan

**Study design** L Paternoster, M Standl, CM Chen, L Duijts, JP Thyssen, B Feenstra, PM Sleiman, M Kerkhof, E Dermitzakis, AL Hartikainen, A Pouta, J Pekkanen, M Kaakinen, GD Smith, J Henderson, HE Wichmann, N Novak, A Linneberg, T Menné, EA Nohr, A Hofman, AG Uitterlinden, CM van Duijn, F Rivadeneira, JC de Jongste, RJ van der Valk, HA Boyd, JC Murray, TD Spector, P Sly, W Nystad, A Simpson, D Postma, GH Koppelman, HA Smit, H Bisgaard, DI Boomsma, A Custovic, NM Probst-Hensch, H Hakonarson, M Melbye, DL Jarvis, VW Jaddoe, C Gieger, MR Jarvelin, J Heinrich, DM Evans, S Weidinger

**Writing paper** L Paternoster, M Standl, A Ramasamy, K Bønnelykke, J Heinrich, DM Evans, S Weidinger

**Data collection** K Bønnelykke, L Duijts, JP Thyssen, B Feenstra, R Myhre, M Kerkhof, R Fölster-Holst, E Dermitzakis, SB Montgomery, AL Hartikainen, A Pouta, J Pekkanen, M Kaakinen, DL Duffy, PA Madden, AC Heath, GW Montgomery, PJ Thompson, MC Matheson, PL Souëf, J Henderson, SM Ring, W McArdle, A Linneberg, T Menné, EA Nohr, JC de Jongste, RJ van der Valk, M Wjst, R Jogi, F Geller, HA Boyd, JC Murray, F Mentch, TD Spector, V Bataille, CE Pennell, PG Holt, P Sly, M Imboden, W Nystad, A Simpson, D Postma, GH Koppelman, HA Smit, B Chawes, E Kreiner-Møller, H Bisgaard, E Melén, DI Boomsma, A Custovic, B Jacobsson, NM Probst-Hensch, LJ Palmer, M Melbye, DL Jarvis, VW Jaddoe, NG Martin, MR Jarvelin, J Heinrich, S Weidinger

**Genotyping** R Myhre, A Franke, AIF Blakemore, JL Buxton, P Deloukas, SM Ring, N Klopp, E Rodríguez, W McArdle, A Linneberg, AG Uitterlinden, F Rivadeneira, M Wjst, C Kim, CE Pennell, T Illig, C Söderhäll, B Jacobsson, LJ Palmer, MR Jarvelin

**Revising and reviewing paper** L Paternoster, M Standl, CM Chen, A Ramasamy, K Bønnelykke, L Duijts, MA Ferreira, AC Alves, JP Thyssen, E Albrecht, H Baurecht, B Feenstra, PM Sleiman, P Hysi, NM Warrington, I Curjuric, R Myhre, JA Curtin, MM Groen-Blokhuis, M Kerkhof, A Sääf, A Franke, D Ellinghaus, R Fölster-Holst, E Dermitzakis, SB Montgomery, AL Hartikainen, A Pouta, J Pekkanen, AIF Blakemore, JL Buxton, M Kaakinen, DL Duffy, PA Madden, AC Heath, GW Montgomery, PJ Thompson, MC Matheson, PL Souëf, BS Pourcain, GD Smith, J Henderson, JP Kemp, NJ Timpson, P Deloukas, SM Ring, HE Wichmann, M Müller-Nurasyid, N Novak, N Klopp, E Rodríguez, W McArdle, A Linneberg, T Menné, EA Nohr, A Hofman, AG Uitterlinden, CM van Duijn, F Rivadeneira, JC de Jongste, RJ van der Valk, M Wjst, R Jogi, F Geller, HA Boyd, JC Murray, C Kim, F Mentch, M March, M Mangino, TD Spector, V Bataille, CE Pennell, PG Holt, P Sly, CMT Tiesler, E Thiering, T Illig, M Imboden, W Nystad, A Simpson, JJ Hottenga, D Postma, GH Koppelman, HA Smit, C Söderhäll, B Chawes, E Kreiner-Møller, H Bisgaard, E Melén, DI Boomsma, A Custovic, B Jacobsson, NM Probst-Hensch, LJ Palmer, D



Glass, H Hakonarson, M Melbye, DL Jarvis, VW Jaddoe, C Gieger, D Strachan, NG Martin, MR Jarvelin, J Heinrich, DM Evans, S Weidinger

## Acknowledgments

The full list of acknowledgements for each study is in the Supplementary Note.

## APPENDIX

### Methods

#### Discovery Analysis

For the discovery analysis we used 5,606 AD cases and 20,565 controls of European descent from 16 population-based cohorts, 10 of which were birth cohorts. Details on sample recruitment, phenotypes and summary details for each collection are given in the Supplementary Methods and in Supplementary Table 1. Genome-wide genotyping was performed independently in each cohort with the use of various standard genotyping technologies (see Supplementary Table 2). Each study independently conducted imputation with reference to HapMap release 21 or 22 CEU phased genotypes, and performed association analysis using logistic regression models based on an expected allelic-dosage model for SNPs, adjusting for sex and ancestry-informative principal components, as necessary. SNPs with a minor allele frequency <1% and poor imputation quality ( $R^2 < 0.3$  if using MACH or  $\text{proper-info} < 0.4$  if using IMPUTE imputation algorithm) were excluded. After genomic control at individual study levels, we combined association data for ~2.5 million imputed and genotyped autosomal SNPs into an inverse-variance fixed-effects additive-model meta-analysis. There was little evidence for population stratification at study level ( $\lambda_{GC} \leq 1.08$ , Supplementary Table 2) or at the meta-analysis level ( $\lambda_{GC} = 1.02$ ), and the quantile-quantile (Q-Q) plot of the meta-statistic showed a marked excess of detectable association signals well beyond those expected by chance (Supplementary Fig.1).

#### Replication Analysis

For replication we selected the most strongly associated SNPs from the 10 most strongly associated loci in the discovery meta-analysis (all were  $P < 10^{-5}$  in stage 1, Table 1). These SNPs were analysed using *in silico* data from 11 GWA sample sets not included in the discovery meta-analysis and additional *de novo* genotyping in a further 3 studies (Supplementary Tables 1,2), for a maximum possible replication sample size of 5,419 cases and 19,833 controls, all of European descent. Each study again conducted the association analyses using a logistic regression model with similar covariate adjustments, based on expected allelic dosage for the *in silico* studies and allele counts in the *de novo* genotyping studies and the results were meta-analysed in Stata 11.1 software (Statacorp LP, Texas, USA). We applied a threshold of  $p < 5 \times 10^{-8}$  for genome-wide significance and tested for overall heterogeneity of the discovery and replication studies using the Cochran's Q-statistic.

#### ImmunoChip Analysis Methods

We evaluated 1,553 German AD cases and 3,640 German population controls. Cases were obtained from German university hospitals (Technical University Munich as part of the GENEVA study, and University of Kiel). AD was diagnosed on the basis of a skin examination by experienced dermatologists according to standard criteria in the presence of chronic or chronically relapsing pruritic dermatitis with the typical morphology and distribution<sup>6</sup>. Controls were derived from the KORA population-based surveys<sup>35</sup> and the previously described population-based Popgen Biobank<sup>36</sup>. 767 of the cases and 983 of the

controls were also part of the replication stage. Samples with > 10% missing data, individuals from each pair of unexpected duplicates or relatives, as well as individuals with outlier heterozygosities of  $\pm 5$  s.d. away from the mean were excluded. The remaining Immunochip samples were tested for population stratification using the principal components stratification method, as implemented in EIGENSTRAT<sup>37</sup>. The results of principal component analysis revealed no evidence for population stratification. SNPs that had >5% missing data, a minor allele frequency <1% and exact Hardy-Weinberg equilibrium  $P_{\text{controls}} < 10^{-4}$  were excluded. Association  $P$  values were calculated using  $\chi^2$  tests (d.f. = 1) and conditional association was analyzed using logistic regression both implemented in PLINK<sup>38</sup> from where we also derived odds ratios and their respective confidence intervals.

### ALSPAC Expression Analysis Methods

997 unrelated ALSPAC individuals for which LCLs had been generated had RNA extracted using Qiagen's RNeasy extraction kit and amplified using Ambion's illumina totalprep 96 RNA amplification kit and expression surveyed using the Illumina HT-12 v3 bead arrays. Each individual was run with 2 replicates. Expression data was normalized by quantile normalization between replicates and then median normalization across individuals. 949 ALSPAC individuals had both expression levels and imputed genome-wide SNP data available (see ALSPAC replication cohort genotyping above). For each of the three AD replicated SNPs (rs479844, rs2164983 and rs2897442, we used linear regression in Mach2QTL to investigate the association between each SNP and any transcript within +/- 500kb of the SNP.


### References

1. Bieber T. Atopic dermatitis. *N Engl J Med.* 2008; 358:1483–1494. [PubMed: 18385500]
2. Brown SJ, McLean WHI. Eczema genetics: current state of knowledge and future goals. *J Invest Dermatol.* 2009; 129:543–552. [PubMed: 19209157]
3. Morar N, Willis-Owen SAG, Moffatt MF, Cookson WOCM. The genetics of atopic dermatitis. *J Allergy Clin Immunol.* 2006; 118:24–34. 35–6. [PubMed: 16815134]
4. Palmer CNA, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nat Genet.* 2006; 38:441–446. [PubMed: 16550169]
5. Rodríguez E, et al. Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. *J Allergy Clin Immunol.* 2009; 123:1361–70. e7. [PubMed: 19501237]
6. Esparza-Gordillo J, et al. A common variant on chromosome 11q13 is associated with atopic dermatitis. *Nat Genet.* 2009; 41:596–601. [PubMed: 19349984]
7. Sun LD, et al. Genome-wide association study identifies two new susceptibility loci for atopic dermatitis in the Chinese Han population. *Nat Genet.* 2011; 43:690–694. [PubMed: 21666691]
8. Moffatt MF, et al. A large-scale, consortium-based genomewide association study of asthma. *N Engl J Med.* 2010; 363:1211–1221. [PubMed: 20860503]
9. Li B, et al. *Ovo1* regulates meiotic pachytene progression during spermatogenesis by repressing *Id2* expression. *Development.* 2005; 132:1463–1473. [PubMed: 15716349]
10. Nair M, et al. *Ovo1* regulates the growth arrest of embryonic epidermal progenitor cells and represses *c-myc* transcription. *J Cell Biol.* 2006; 173:253–264. [PubMed: 16636146]
11. Dai X, et al. The *ovo* gene required for cuticle formation and oogenesis in flies is involved in hair formation and spermatogenesis in mice. *Genes Dev.* 1998; 12:3452–3463. [PubMed: 9808631]
12. Kowantetz M, Valcourt U, Bergström R, Heldin CH, Moustakas A. *Id2* and *Id3* define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. *Mol Cell Biol.* 2004; 24:4241–4254. [PubMed: 15121845]
13. Li B, et al. The *LEF1*/ $\beta$ -catenin complex activates *mov1*, a mouse homolog of *Drosophila ovo* required for epidermal appendage differentiation. *Proc Natl Acad Sci U S A.* 2002; 99:6064–6069. [PubMed: 11983900]

14. Owens P, Han G, Li AG, Wang XJ. The role of Smads in skin development. *J Invest Dermatol*. 2008; 128:783–790. [PubMed: 18337711]
15. Widelitz RB. Wnt signaling in skin organogenesis. *Organogenesis*. 2008; 4:123–133. [PubMed: 19279724]
16. Buschke S, et al. A decisive function of transforming growth factor- $\beta$ /Smad signaling in tissue morphogenesis and differentiation of human HaCaT keratinocytes. *Mol Biol Cell*. 2011; 22:782–794. [PubMed: 21289094]
17. Maganga R, et al. Secreted Frizzled related protein-4 (sFRP4) promotes epidermal differentiation and apoptosis. *Biochem Biophys Res Commun*. 2008; 377:606–611. [PubMed: 18938133]
18. Romanowska M, et al. Wnt5a exhibits layer-specific expression in adult skin, is upregulated in psoriasis, and synergizes with type 1 interferon. *PLoS One*. 2009; 4:e5354. [PubMed: 19399181]
19. Nica AC, et al. The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. *PLoS Genet*. 2011; 7:e1002003. [PubMed: 21304890]
20. Apte SS. A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms. *J Biol Chem*. 2009; 284:31493–31497. [PubMed: 19734141]
21. Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. *Biochem J*. 2005; 386:15–27. [PubMed: 15554875]
22. Pollard TD. The cytoskeleton, cellular motility and the reductionist agenda. *Nature*. 2003; 422:741–745. [PubMed: 12700767]
23. Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. *Cell*. 2003; 112:453–465. [PubMed: 12600310]
24. Winder SJ. Structural insights into actin-binding, branching and bundling proteins. *Curr Opin Cell Biol*. 2003; 15:14–22. [PubMed: 12517699]
25. Goetz SC, Anderson KV. The primary cilium: a signalling centre during vertebrate development. *Nat Rev Genet*. 2010; 11:331–344. [PubMed: 20395968]
26. Mosimann C, Hausmann G, Basler K. Beta-catenin hits chromatin: regulation of Wnt target gene activation. *Nat Rev Mol Cell Biol*. 2009; 10:276–286. [PubMed: 19305417]
27. Chang M, et al. Variants in the 5q31 cytokine gene cluster are associated with psoriasis. *Genes Immun*. 2008; 9:176–181. [PubMed: 18075513]
28. Nair RP, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. *Nat Genet*. 2009; 41:199–204. [PubMed: 19169254]
29. Li Y, et al. The 5q31 variants associated with psoriasis and Crohn's disease are distinct. *Hum Mol Genet*. 2008; 17:2978–2985. [PubMed: 18614543]
30. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature*. 2007; 447:661–678. [PubMed: 17554300]
31. Weidinger S, et al. Genome-wide scan on total serum IgE levels identifies FCER1A as novel susceptibility locus. *PLoS Genet*. e1000166; 4:2008. [PubMed: 18846228]
32. Vercelli D. Discovering susceptibility genes for asthma and allergy. *Nat Rev Immunol*. 2008; 8:169–182. [PubMed: 18301422]
33. Kleinjan DA, van Heyningen V. Long-range control of gene expression: emerging mechanisms and disruption in disease. *Am J Hum Genet*. 2005; 76:8–32. [PubMed: 15549674]
34. Sproul D, Gilbert N, Bickmore WA. The role of chromatin structure in regulating the expression of clustered genes. *Nat Rev Genet*. 2005; 6:775–781. [PubMed: 16160692]
35. Holle R, Happich M, Löwel H, Wichmann HE, MONICA/KORA Study Group. KORA—a research platform for population based health research. *Gesundheitswesen*. 2005; 67(Suppl 1):S19–S25. [PubMed: 16032513]
36. Krawczak M, et al. PopGen: population-based recruitment of patients and controls for the analysis of complex genotype-phenotype relationships. *Community Genet*. 2006; 9:55–61. [PubMed: 16490960]
37. Price A, et al. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet*. 2006; 38:904–909. [PubMed: 16862161]



38. Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet.* 2007; 81:559–575. [PubMed: 17701901]






**Figure 1. Manhattan plot for the discovery genome-wide association meta-analysis of atopic dermatitis**  
after excluding all SNPs MAF<1% and Rsqr<0.3 or proper\_info<0.4.  $\lambda=1.017$ . SNPs with  $p < 1 \times 10^{-5}$  are shown in red.







**Figure 2. Forest plots for the association of (a) rs479844, (b) rs2164983 and (c) rs2894772 with atopic dermatitis**

All OR are reported with the minor allele (shown in brackets) as the effect allele. \*MoBa imputation quality score was 'info' from PLINK.

GENR=Generation R. rs2164983 was not included in the HapMap release 21 and so was missing for some discovery cohorts.

Black points indicate the Odds Ratios (ORs) and the horizontal lines represent the 95% confidence intervals (CIs) for each study. Arrows are used to show where a CI extends beyond the range of the plot.

The sizes of the red and blue boxes indicate the relative weight of each study (using inverse variance weighting). Blue boxes indicate SNPs that were imputed and red boxes indicate SNPs on the genome-wide genotyping chip for the discovery cohorts and either on the genome-wide genotyping chip or individually genotyped for the replication cohorts. Only Health2006, KORA/GENEVA and NFBC86' underwent individual SNP genotyping. The subtotals (for discovery and replication) and overall ORs and CIs are indicated by the centre and range of the diamonds.

**Table 1**  
**Discovery and replication results of the loci associated with atopic dermatitis**

Results are for the fixed effect inverse-variance meta-analysis, with genomic control applied to the individual studies in the discovery meta-analysis. Stage I denotes discovery, II denotes replication and I+II denotes the combined analysis. The heterogeneity p-value (het pvalue), testing for overall heterogeneity between all discovery and replication studies was generated using Cochran's Q-test for heterogeneity. All OR (odds ratios) are given with the minor allele representing the effect allele. CI denotes the confidence interval

Chr	SNP	Position (bp)	Gene	Effect allele	Other allele	Effect allele freq	Stage	N	OR (95% CI)	pvalue	het pvalue
11	rs479844	65308533	OVOL1	A	G	0.44	I	26,151	0.89 (0.85, 0.93)	<b>7.8E-07</b>	
							II	25,098	0.87 (0.83,0.92)	<b>2.4E-08</b>	
							I+II	51,249	0.88 (0.85,0.91)	<b>1.1E-13</b>	0.23
19	rs2164983 *	8650381	ACTL9	A	C	0.15	I	17,403	1.22 (1.13, 1.32)	<b>1.8E-07</b>	
							II	22,996	1.11 (1.04,1.19)	<b>0.002</b>	
							I+II	40,399	1.16 (1.10,1.22)	<b>7.1E-09</b>	0.004
5	rs2897442	132076926	KIF3A	C	T	0.29	I	26,164	1.12 (1.07, 1.18)	<b>7.8E-06</b>	
							II	25,064	1.09 (1.04,1.15)	<b>0.001</b>	
							I+II	51,228	1.11 (1.07,1.15)	<b>3.8E-08</b>	0.52

\* rs2164983 was not included in the HapMap release 21 and so was missing for some discovery cohorts. This SNP showed evidence of heterogeneity ( $p=0.004$ ). The random effects combined (I+II) result for this SNP was OR=1.14 (95%CI 1.05, 1.24)  $p=0.001$ .